North America Fibromyalgia Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class (Anticonvulsants, Antidepressants, Muscle Relaxants and Others), By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Fibromyalgia Treatment Market, by Drug Class
1.4.2 North America Fibromyalgia Treatment Market, by Distribution Channel
1.4.3 North America Fibromyalgia Treatment Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. North America Fibromyalgia Treatment Market by Drug Class
3.1 North America Anticonvulsants Market by Country
3.2 North America Antidepressants Market by Country
3.3 North America Muscle Relaxants Market by Country
3.4 North America Others Market by Country

Chapter 4. North America Fibromyalgia Treatment Market by Distribution Channel
4.1 North America Drug stores & Retail Pharmacies Market by Country
4.2 North America Hospital Pharmacies Market by Country
4.3 North America Online Providers Market by Country

Chapter 5. North America Fibromyalgia Treatment Market by Country
5.1 US Fibromyalgia Treatment Market
5.1.1 US Fibromyalgia Treatment Market by Drug Class
5.1.2 US Fibromyalgia Treatment Market by Distribution Channel
5.2 Canada Fibromyalgia Treatment Market
5.2.1 Canada Fibromyalgia Treatment Market by Drug Class
5.2.2 Canada Fibromyalgia Treatment Market by Distribution Channel
5.3 Mexico Fibromyalgia Treatment Market
5.3.1 Mexico Fibromyalgia Treatment Market by Drug Class
5.3.2 Mexico Fibromyalgia Treatment Market by Distribution Channel
5.4 Rest of North America Fibromyalgia Treatment Market
5.4.1 Rest of North America Fibromyalgia Treatment Market by Drug Class
5.4.2 Rest of North America Fibromyalgia Treatment Market by Distribution Channel

Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 SWOT Analysis
6.2 AbbVie, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Acquisition and Mergers:
6.3 Novartis AG
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Acquisition and Mergers:
6.4 Eli Lilly And Company
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.5 Amneal Pharmaceuticals, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental Analysis
6.5.4 Research & Development Expenses
6.6 Teva Pharmaceutical Industries Ltd.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expenses
6.7 Zydus Lifesciences Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Trials and Approvals:
6.8 Lupin Limited
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Recent strategies and developments:
6.8.3.1 Trials and Approvals:
6.9 Viatris, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental Analysis
6.9.4 Research & Development Expense
6.10. Sun Pharmaceutical Industries Ltd.
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expenses